As noticed, we found a statistically significant difference among the study groups regarding WHtR, higher in NAFLD treated mutated group in comparison to NAFLD wild type controls (p = 0.005) CAP, higher in NAFLD treated mutated group in comparison to NAFLD wild type controls and NAFLD wild type treated group (p = 0.0002 for both), CRP, higher in NAFLD treated mutated group in comparison to NAFLD wild type controls (p = 0.045). The gene discussed is CRP; the disease is metabolic dysfunction-associated steatotic liver disease.